Metastatic Colorectal Adenocarcinoma (DBCOND0058150)

Identifiers

Synonyms

Metastatic Adenocarcinoma of the Colon or Rectum

Associated Data

Indicated Drugs and Targets

Not Available

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT01765790	Phase 1 Study of Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody in Solid Tumors	Olive oil	treatment	1	completed
NCT02997228	Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer, the COMMIT Study	Atezolizumab Bevacizumab Fluorouracil Leucovorin Oxaliplatin	treatment	3	recruiting
NCT06102902	Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer	Cetuximab Encorafenib	treatment	1	recruiting
NCT04511039	Trifluridine/Tipiracil and Talazoparib for the Treatment of Patients With Locally Advanced or Metastatic Colorectal or Gastroesophageal Cancer	TAS-102 Talazoparib Thymidine Tipiracil Trifluridine	treatment	1	recruiting
NCT05356897	Tucatinib Combined with Trastuzumab and TAS-102 for the Treatment of HER2 Positive Metastatic Colorectal Cancer in Molecularly Selected Patients, 3T Study	TAS-102 Tipiracil Trastuzumab Trifluridine Tucatinib	treatment	2	withdrawn
NCT05672316	Botensilimab, Balstilimab and Regorafenib for the Treatment of Patients with Microsatellite Stable Metastatic Colorectal Cancer Who Have Progressed on Prior Chemotherapy	Balstilimab Botensilimab Regorafenib	treatment	1 / 2	active_not_recruiting
NCT06043713	Autologous CD8+ and CD4+ Transgenic T Cells Expressing High Affinity KRASG12V Mutation-Specific T Cell Receptors (FH-A11KRASG12V-TCR) in Treating Patients With Metastatic Pancreatic, Colorectal and Non-Small Cell Lung Cancers With KRAS G12V Mutations	Bendamustine Cyclophosphamide Fludarabine	treatment	1	recruiting
NCT06336902	Botensilimab Plus Balstilimab and Fasting Mimicking Diet Plus Vitamin C for Patients With KRAS-Mutant Metastatic Colorectal Cancer	Balstilimab Botensilimab	treatment	1	not_yet_recruiting
NCT04117945	Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancer	Cetuximab Irinotecan Panitumumab Regorafenib	treatment	2	active_not_recruiting
NCT05312398	CAPRI 2 GOIM Study: Investigate the Efficacy and Safety of a Bio-marker Driven Cetuximab-based Treatment Regimen	Cetuximab Fluorouracil Irinotecan Leucovorin	treatment	2	active_not_recruiting
NCT05869097	Trifluridine/Tipiracil Plus Bevacizumab Versus Trifluridine/Tipiracil Monotherapy in Refractory Metastatic Colorectal Cancer	Bevacizumab TAS-102 Tipiracil Trifluridine	Not Available	Not Available	completed
NCT06195670	Clinical Study of Short-course Radiotherapy Followed by Fruquintinib Plus Sintilimab vs Bevacizumab Plus Capecitabine as First Line Treatment in Advanced mCRC	Bevacizumab Capecitabine Fruquintinib Sintilimab	treatment	1 / 2	not_yet_recruiting
NCT02600949	Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal Cancer	Imiquimod Pembrolizumab Sotigalimab	treatment	1	recruiting
NCT04483219	Tyrosine Kinase Inhibitor (TKI) + Anti-PD-1 Antibody in TKI-responded Microsatellite Stability/Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Adenocarcinoma.	No drug interventions	treatment	2	unknown_status
NCT02599324	Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors	Cetuximab Docetaxel Everolimus Ibrutinib Paclitaxel Pembrolizumab	treatment	1 / 2	completed
NCT05627635	FOLFOX and Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX) for the Treatment of Microsatellite Stable (MSS) Metastatic Colorectal Cancer	Balstilimab Bevacizumab Botensilimab Calcium Fluorouracil Leucovorin Levoleucovorin Oxaliplatin	treatment	1 / 2	recruiting
NCT04119830	Rintatolimod and Pembrolizumab for the Treatment of Refractory Metastatic or Unresectable Colorectal Cancer	Pembrolizumab Rintatolimod	treatment	2	withdrawn
NCT05673148	Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, The ERASur Study	No drug interventions	treatment	3	recruiting
NCT06031376	Fruquintinib With PD-1 Inhibitors Versus TAS-102 With Bevacizumab in Late-Line mCRC	Bevacizumab Fruquintinib TAS-102 Tipiracil Trifluridine	Not Available	Not Available	completed
NCT05130060	A Vaccine (PolyPEPI1018 Vaccine) and TAS-102 for the Treatment of Metastatic Colorectal Cancer	TAS-102 Tipiracil Trifluridine	treatment	1	completed
NCT03610490	Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Colorectal Cancer, or Pancreatic Ductal Adenocarcinoma	Cyclophosphamide Fludarabine Human interleukin-2 Lifileucel Teceleukin	treatment	2	terminated
NCT02023333	Regorafenib in Good Performance Status Patients With Newly Diagnosed Metastatic Colorectal Adenocarcinoma	Regorafenib	treatment	2	active_not_recruiting
NCT03087071	Panitumumab With or Without Trametinib in Treating Patients With Stage IV Colorectal Cancer	Panitumumab Trametinib	treatment	2	active_not_recruiting
NCT03043313	Tucatinib Plus Trastuzumab in Patients With HER2+ Colorectal Cancer	Trastuzumab Tucatinib	treatment	2	completed
NCT01900717	Evaluation of Bevacizumab in Combination With First-Line Chemotherapy in Patients Aged 75 Years of Older With Metastatic Colorectal Adenocarcinoma (Prodige20)	Bevacizumab Fluorouracil Irinotecan Leucovorin Oxaliplatin	other	2	completed
NCT04362839	Regorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metastatic Colorectal Cancer	Ipilimumab Nivolumab Regorafenib	treatment	1	active_not_recruiting
NCT04729322	Fecal Microbiota Transplant and Re-introduction of Anti-PD-1 Therapy (Pembrolizumab or Nivolumab) for the Treatment of Metastatic Colorectal Cancer in Anti-PD-1 Non-responders	Fecal microbiota Metronidazole Neomycin Nivolumab Pembrolizumab Vancomycin	treatment	2	active_not_recruiting
NCT06575725	Botensilimab, Balstilimab and Regorafenib or Botensilimab and Balstilimab for the Treatment of Advanced or Metastatic Microsatellite Stable Colorectal Cancer	Balstilimab Botensilimab Regorafenib	treatment	2	not_yet_recruiting
NCT04044430	Encorafenib, Binimetinib, and Nivolumab in Treating Microsatellite Stable BRAF V600E Metastatic Colorectal Cancer	Binimetinib Encorafenib Nivolumab	treatment	1	terminated
NCT06083974	Metastatic Left Colon and Rectal Cancer Treatment With Anti_EGFR Targeted Therapy	No drug interventions	Not Available	Not Available	completed
NCT01639131	Gemcitabine and Docetaxel in Patients With Relapsed or Refractory Metastatic Colorectal Adenocarcinoma	Docetaxel Filgrastim Gemcitabine Pegfilgrastim	treatment	2	terminated
NCT05942768	Anti-PD-1 Antibody Plus Regorafenib in Refractory Microsatellite Stable Metastatic Colorectal Cancer	Regorafenib	Not Available	Not Available	completed